ClinicalTrials.gg
CompletedNCT06559488Updated Aug 27, 2024

IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes

An interventional study of Bevacizumab Injection [Avastin] and Pars Plana Vitrectomy in Diabetic Retinopathy and Vitreous Hemorrhage, sponsored by Universitas Padjadjaran. Completed at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Universitas Padjadjaran · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 years 4 months after the study started (first participant enrolled Apr 2018, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing bevacizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Bevacizumab · Diabetic Retinopathy.

Enrollment
22nd of 28
18 · median 30
Started
2018
the only one that year
No phase
7 of 33
none open now
Registered
31st of 33
by date

Among the 33 studies testing bevacizumab in Diabetic Retinopathy, this one is the 22nd largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2018, is one of 7 with no phase, and was the 31st registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 33 studies testing bevacizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing bevacizumab in Diabetic Retinopathy, or all of them as a file.
02

Study summary

Recurrent vitreous hemorrhage following pars plana vitrectomy (PPV) for proliferative diabetic retinopathy remains a significant complication with reported incidence ranging from 11 to 75%. Early and late recurrences are associated with various factors, including residual blood, fibrovascular tissue, and neovascularization. Despite attempts to reduce this complication with therapies like anti-fibrinolytic agents, gas tamponade, and peripheral cryotherapy, the outcomes remain unsatisfactory.

Read the detailed description

Recurrent vitreous hemorrhage following pars plana vitrectomy (PPV) for proliferative diabetic retinopathy remains a significant challenge with high incidence and negative impact on visual outcomes. Despite various treatments, intravitreal bevacizumab (IVB) has shown potential in reducing post-operative vitreous hemorrhage (PO-VH). This study aims to determine the efficacy and safety of intraoperative IVB in preventing PO-VH in patients undergoing vitrectomy for diabetic vitreous hemorrhage. This prospective, randomized controlled trial compared patients receiving intraoperative IVB to a control group. The primary outcome was PO-VH incidence at one month, with secondary outcomes including visual acuity change, time to VH clearance, and safety. Outcome assessors were masked to the study treatment. Data on demographics, medical history, visual acuity, VH grading, intraoperative findings, and postoperative complications will be collected. Statistical analysis compared PO-VH incidence and other outcomes between groups. This study will provide valuable evidence on the efficacy and safety of intraoperative IVB in preventing PO-VH, contributing to improved clinical practice and patient outcomes.

03

Conditions studied

  • Diabetic Retinopathy
  • Vitreous Hemorrhage

Keywords

  • Diabetic vitreous hemorrhage
  • Intravitreal bevacizumab
  • Pars plana vitrectomy
  • Proliferative diabetic retinopathy
  • Recurrent vitreous hemorrhage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with spontaneous, non-clearing vitreous hemorrhage for at least one month as the initial vitrectomy indication for diabetic retinopathy.

Exclusion criteria

Exclusion Criteria:

  • Patients with tractional retinal detachment (ART)
  • Patients with severe fibrovascular traction,
  • Patients with intravitreal gas or silicone oil tamponade at the end of surgery
  • Patients with other eye diseases besides diabetic vitreous hemorrhage
  • Patients with history of intravitreal bevacizumab injection in the last 3 months before surgery
  • Patients with other health condition includes uncontrolled hypertension, a history of coagulopathy
  • Patients with inability to attend follow-up examinations for at least 1 month
  • Patients taking anti-aggregation and anti- medications with abnormal bleeding time (BT) and clotting time (CT)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Bevacizumab Intravitreal

    Ten patients underwent pars plana vitrectomy under local anesthesia. Vitrectomy used 3 23-gauge sclerotomies, triamcinolone for hyaloid cleaning, and hemostasis by elevated pressure, endo-diathermy, or laser. Panretinal laser applied to unlasered retina. Retina examined for tears or bleeding. IOP set at 20mmHg, sclerotomies sutured if needed. Post-vitrectomy, 1.25 mg bevacizumab injected via 30-gauge needle in superotemporal or inferotemporal pars plana.

    Drug: Bevacizumab Injection [Avastin] · Procedure: Pars Plana Vitrectomy

  • Experimental
    Control

    Eight patients underwent pars plana vitrectomy under local anesthesia. Vitrectomy used 3 23-gauge sclerotomies, triamcinolone for hyaloid cleaning, and hemostasis by elevated pressure, endo-diathermy, or laser. Panretinal laser applied to unlasered retina. Retina examined for tears or bleeding. IOP set at 20mmHg, sclerotomies sutured if needed.

    Procedure: Pars Plana Vitrectomy

Interventions

  • DrugBevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.

    Also known as: Pars Plana Vitrectomy

  • ProcedurePars Plana Vitrectomy

    routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Vitreal Hemorrhage Post-Operative

    Calculation of incidence of Vitreal Hemorrhage Post Operative based on grading (Grade 0, Grade 1, Grade 2, Grade 3, Grade 4) between two groups; higher grades are related to worse outcomes

    Time frame: Day 1, 7, and 30

Secondary outcomes

  1. Post operative visual Acuity, compared between groups

    Visual acuity measured with a Snellen chart was converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. Snellen visual acuity of finger counting was categorized as log MAR 2.0, and hand motion as log MAR 3.0

    Time frame: Day 1, 7, and 30

07

Study locations

1 site
  • Cicendo Eye Hospital
    Bandung, Jawab Barat 40117, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Mar 2019, 11 months.

Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's 11 months is below that.

Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 19, 2024
StartActual
Apr 2, 2018
Primary completionActual
Mar 31, 2019
CompletionActual
Mar 31, 2019
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06559488
Lead sponsor
Universitas Padjadjaran
Collaborators
Cicendo Eye Hospital
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Apr 2, 2018
Primary completion
Mar 31, 2019
Completion
Mar 31, 2019
Last update
Aug 27, 2024

Study contacts

Mohamad Eko Prayogo, MD
principal investigator · Faculty of Medicine Universitas Padjadjaran

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion